Detection of unreported usage of the antiretroviral drug lamivudine in two blood donors
Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
SALLES, Nanci
NOGUEIRA, Fatima
Citação
TRANSFUSION, v.63, n.11, p.2106-2113, 2023
Resumo
Background Unreported HIV antiretroviral (ARV) drug usage by blood donors compromises the ability to detect evidence of HIV infection in blood screening tests and represents a risk for blood transfusion safety. Our objective was to determine the frequency of undeclared ARV drug use by blood donors with altered HIV markers.Study Design and Methods This was a retrospective cross-sectional analysis of donations that were tested for HIV antibody (ab), antigen (ag), and RNA by chemiluminescent immunoassay and nucleic acid screening tests. Positive samples were retested and were subjected to ARV drug testing by high-performance liquid chromatography-tandem mass spectrometry.Results Of 345,252 blood donations, 361 (0.1%) were positive on initial testing. Samples from 296 (81.9%) of these donations were available for further analysis. The presence of HIV ab/ag and/or RNA was confirmed in 83 (28.0%) of these samples. All 296 bloods were subjected to ARV testing. The ARV drug lamivudine, at 11.3 and 6.7 ng/mL, was detected in 2 of 83 (2.4%) donations that were HIV positive. Other drugs were not detected.Conclusion Unreported ARV usage was identified in two candidates for blood donation. More intensive efforts to educate donors about disclosure and to investigate the extent of this phenomenon in Brazil are needed.
Palavras-chave
blood donors, blood transfusion, HIV infection, HIV therapy, lamivudine, transfusion safety
Referências
- [Anonymous], GUIA INCL CRIT TRIAG
- Brasil, PAIN PREP 2022
- Brasil, REL MON CLIN HIV 202
- Brasil, 2021, B EPIDEMIOLOGICO HEP
- Busch MP, 2022, TRANSFUSION, V62, P1334, DOI 10.1111/trf.16931
- Busch MP, 2019, BLOOD, V133, P1854, DOI 10.1182/blood-2018-11-833996
- Calcagno A, 2013, ANTIMICROB AGENTS CH, V57, P1840, DOI 10.1128/AAC.02434-12
- Calza L, 2017, HIV MED, V18, P474, DOI 10.1111/hiv.12478
- Candotti D, 2004, J VIROL METHODS, V118, P39, DOI 10.1016/j.jviromet.2004.01.017
- Custer B, 2020, BLOOD, V136, P1351, DOI 10.1182/blood.2020006890
- Mateos SDG, 2021, VOX SANG, V116, P207, DOI 10.1111/vox.13002
- de Souza MS, 2016, CLIN INFECT DIS, V63, P555, DOI 10.1093/cid/ciw365
- Donnell D, 2017, AIDS, V31, P2007, DOI [10.1097/qad.0000000000001577, 10.1097/QAD.0000000000001577]
- Eisinger RW, 2019, JAMA-J AM MED ASSOC, V321, P451, DOI 10.1001/jama.2018.21167
- Fonsart J, 2017, J ANTIMICROB CHEMOTH, V72, P478, DOI 10.1093/jac/dkw412
- Hare CB, 2006, CLIN INFECT DIS, V42, P700, DOI 10.1086/500215
- Harvala H, 2022, SEX TRANSM INFECT, V98, P132, DOI 10.1136/sextrans-2021-054981
- Kassutto S, 2005, CLIN INFECT DIS, V40, P868, DOI 10.1086/428127
- Keating SM, 2016, CLIN INFECT DIS, V63, P562, DOI 10.1093/cid/ciw369
- Kenyon C, 2020, CURR OPIN INFECT DIS, V33, P51, DOI 10.1097/QCO.0000000000000621
- Lambotte O, 2005, CLIN INFECT DIS, V41, P1053, DOI 10.1086/433188
- Li JZ, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI149414
- Minzi OM, 2011, THER CLIN RISK MANAG, V7, P441, DOI 10.2147/TCRM.S23625
- Nishiya AS, 2022, VIRUSES-BASEL, V14, DOI 10.3390/v14102214
- Nishiya AS, 2021, TRANSFUSION, V61, P3488, DOI 10.1111/trf.16698
- Poeta J, 2011, J ANTIMICROB CHEMOTH, V66, P2601, DOI 10.1093/jac/dkr360
- Salles NA, 2019, REV SOC BRAS MED TRO, V52, DOI 10.1590/0037-8682-0432-2018
- Salles NA, 2013, TRANSFUSION, V53, P2593, DOI 10.1111/trf.12316
- Sykes W, 2019, J INFECT DIS, V220, P643, DOI 10.1093/infdis/jiz145
- University of Liverpool DoP, FACT SHEETS
- van den Berg K, 2023, TRANSFUSION MED, V33, P277, DOI 10.1111/tme.12957
- van den Berg K, 2021, TRANSFUSION, V61, P2392, DOI 10.1111/trf.16571
- Winston A, 2005, J ANTIMICROB CHEMOTH, V56, P380, DOI 10.1093/jac/dki235